OmniAb, Inc.
OmniAb, Inc. licenses antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The company’s platform combines engineered transgenic animals, computational design, and screening tools to generate and optimize antibody and other target-binding protein candidates for therapeutic development.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueLicenses and access agreements for use of the OmniAb discovery platform.
Research services supporting partner antibody discovery and optimization programs.
Upfront and contingent payments tied to partner program progress and agreements.
Instruments and related consumables sold for discovery workflows.
Payments tied to commercial sales of partner-developed products.
Products
Reported · share of revenue- License and Milestone Revenue52.3 %
- Services38.9 %
- Royalty4.7 %
- X Ploration Revenue4.0 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
OmniAb sells primarily to pharmaceutical and biotechnology companies that need antibody discovery capabilities for therapeutic pipelines. It also serves academic institutions and research organizations that use the platform for discovery research, and its royalty stream depends on partners that successfully advance and commercialize OmniAb-derived programs.
Buy platform access, discovery services, and milestone-based programs to source therapeutic antibodies.
Use OmniAb to accelerate early-stage biologic discovery and candidate optimization.
Access the technology for research discovery and target-binding protein work.
Generate royalties when partner-developed OmniAb-derived products sell in market.
Strategy
OmniAb’s strategy centers on expanding adoption of its antibody discovery platform and converting partner programs into milestones, services, and royalties. The company also emphasizes differentiated technology breadth, including engineered animals, computational tools, and screening methods, to support more complex biologic modalities and deepen partner relationships.
A larger installed base increases recurring access, service, milestone, and royalty opportunities.
Later-stage progression increases milestone recognition and future royalty potential.
Scientific performance and customization drive partner adoption in a competitive discovery market.
Supporting bispecifics, ADCs, CAR-T, and radiotherapeutics widens the addressable market.
Geography
OmniAb is a U.S.-based company with operations and partners serving a global pharmaceutical market. The filings do not provide a country revenue split, but they do indicate royalty exposure to partner product sales in China, showing that commercial outcomes in that market can affect results.
Risks
OmniAb depends on partners to advance discovery and commercialization, so revenue can be affected by program timing, partner execution, and regulatory outcomes outside its control. The business also faces technology adoption risk, cybersecurity/data protection risk, and exposure to geographic demand shifts such as lower partner sales in China.
- Partner development and commercialization dependenceImpact: HighLikelihood: Medium
Milestones, approvals, and royalties depend on partner execution rather than OmniAb control.
Exposure: Discovery programs and royalty streams
- Platform adoption and technology competitionImpact: HighLikelihood: Medium
Customers can choose alternative antibody discovery methods and platforms.
Exposure: New licenses and renewals
- Cybersecurity and data protectionImpact: MediumLikelihood: Low
The company stores sensitive research, IP, and partner data across internal and cloud systems.
Exposure - Capital access and funding needsImpact: MediumLikelihood: Low
If operating cash is insufficient, the company may need external financing.
Exposure: Liquidity and growth investment
- China market exposureImpact: Medium
Royalty revenue was affected by lower partner product sales in China.
Exposure: Partner commercialization and royalty receipts
Accounting
Judgemental itemsDifferent contract components are recognized at different times, creating quarter-to-quarter volatility.
Impact: Reported revenue can shift materially with partner milestones and sales reports
Royalty revenue depends on partner-provided sales data and commercial timing.
Impact: Revenue may lag underlying product sales and vary by geography
Management must compare carrying value to estimated fair value using forecasts and market inputs.
Impact: Could create non-cash charges if assumptions weaken
Acquired technology and related assets require ongoing recoverability assessments.
Impact: Could affect earnings if expected benefits decline
Similar listed companies
Publicly listed companies with a comparable business focus.
Xencor Inc
XNCR · Pharmaceutical Preparations
iBio, Inc.
IBIO · Pharmaceutical Preparations
Omnicell, Inc
OMCL · Electronic Computers
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
REGENXBIO Inc.
RGNX · Biological Products, (No Diagnostic Substances)
Rallybio Corp
RLYB · Pharmaceutical Preparations
Rallybio Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for rare diseases with significant unmet medical need.
Last updated: 24/09/2026